Undiagnosed airflow limitation is common in patients with coronary artery disease and associated with cardiac stress

Respirology

Volumn 21, Issue 1, 2016, Pages 137-142

  Ko, Fanny W S ^a   Yan, Bryan P ^a   Lam, Yat Yin ^a   Chu, Jojo H Y ^a   Chan, Ka Pang ^a   Hui, David S C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

airflow obstruction; cardiac stress; chronic obstructive pulmonary disease; coronary artery disease; ST2

Indexed keywords

PROTEIN ST2; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; BRONCHIECTASIS; CLINICAL ASSESSMENT; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART STRESS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPIROMETRY; UPREGULATION; AGED; BLOOD; CHINA; COMPLICATION; CORONARY ARTERY DISEASE; DIAGNOSTIC ERROR; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; PREVENTION AND CONTROL; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; SMOKING; STATISTICS; STATISTICS AND NUMERICAL DATA;

AGED; AIRWAY OBSTRUCTION; BIOMARKERS; CHINA; CORONARY ARTERY DISEASE; DIAGNOSTIC ERRORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN-1; RISK FACTORS; SMOKING; SPIROMETRY; STATISTICS AS TOPIC;

EID: 84952875652     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12668     Document Type: Article

References (35)

1. Curkendall SM, Lanes S, de Luise C, Stang MR, Jones JK, She D, Goehring E Jr,. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur. J. Epidemiol. 2006; 21: 803-813.
2. World Health Organisation. Cardiovascular diseases, 2014. [Accessed 1 Sep 2014.] Available from URL: http://www.wpro.who.int/mediacentre/factsheets/cardiovascular-disease/en/
3. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S,. Chronic obstructive pulmonary disease: current burden and future projections. Eur. Respir. J. 2006; 27: 397-412.
4. Stone IS, Barnes NC, Petersen SE,. Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease? Heart 2012; 98: 1055-1062.
5. Campo G, Guastaroba P, Marzocchi A, Santarelli A, Varani E, Vignali L, Sangiorgio P, Tondi S, Serenelli C, De Palma R, et al. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest 2013; 144: 750-757.
6. Maclay JD, MacNee W,. Cardiovascular disease in COPD: mechanisms. Chest 2013; 143: 798-807.
7. Mullerova H, Agusti A, Erqou S, Mapel DW,. Cardiovascular comorbidity in COPD: systematic literature review. Chest 2013; 144: 1163-1178.
8. Soriano JB, Rigo F, Guerrero D, Yanez A, Forteza JF, Frontera G, Togores B, Agusti A,. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest 2010; 137: 333-340.
9. Vasile VC, Jaffe AS,. Emerging biomarkers for acute heart conditions. Curr. Opin. Cardiol. 2014; 29: 312-318.
10. Michelsen KS, Doherty TM, Shah PK, Arditi M,. TLR signaling: an emerging bridge from innate immunity to atherogenesis. J. Immunol. 2004; 173: 5901-5907.
11. Meisel C, Bonhagen K, Lohning M, Coyle AJ, Gutierrez-Ramos JC, Radbruch A, Kamradt T,. Regulation and function of T1/ST2 expression on CD4+ T cells: induction of type 2 cytokine production by T1/ST2 cross-linking. J. Immunol. 2001; 166: 3143-3150.
12. Ferris BG,. Recommended respiratory disease questionnaire for use with adults and children in epidemiology research. Am. Rev. Respir. Dis. 1978; 118: 7-53.
13. Mahler DA, Wells CK,. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93: 580-586.
14. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. Eur. Respir. J. 2005; 26: 319-338.
15. Ip MS, Ko FW, Lau AC, Yu WC, Tang KS, Choo K, Chan-Yeung MM,. Updated spirometric reference values for adult Chinese in Hong Kong and implications on clinical utilization. Chest 2006; 129: 384-392.
16. National Heart, Lung and Blood Institute, World Health Organization. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2013. 2013. [Accessed 1 Feb 2013.] Available from URL: http://www.goldcopd.org/guidelines-resources.html.
17. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166: 111-117.
18. Borg GA,. Psychophysical bases of perceived exertion. Med. Sci. Sports Exerc. 1982; 14: 377-381.
19. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2015; 28: 1-39.e14.
20. Finkelstein J, Cha E, Scharf SM,. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int. J. Chron. Obstruct. Pulmon. Dis. 2009; 4: 337-349.
21. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 2005; 95: 948-954.
22. Shah KB, Kop WJ, Christenson RH, Diercks DB, Henderson S, Hanson K, Li SY, deFilippi CR,. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin. Chem. 2011; 57: 874-882.
23. Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, Vazquez R, Puig T, Valdes M, Cinca J, de Luna AB, Bayes-Genis A,. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 2009; 54: 2174-2179.
24. Breidthardt T, Balmelli C, Twerenbold R, Mosimann T, Espinola J, Haaf P, Thalmann G, Moehring B, Mueller M, Meller B, et al. Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. J. Card. Fail. 2013; 19: 821-828.
25. Manzano-Fernandez S, Januzzi JL, Pastor-Perez FJ, Bonaque-Gonzalez JC, Boronat-Garcia M, Pascual-Figal DA, Montalban-Larrea S, Navarro-Penalver M, Andreu-Cayuelas JM, Valdes M,. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology 2012; 122: 158-166.
26. Hacker S, Lambers C, Pollreisz A, Hoetzenecker K, Lichtenauer M, Mangold A, Niederpold T, Hacker A, Lang G, Dworschak M, et al. Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD. J. Clin. Lab. Anal. 2009; 23: 372-379.
27. Benoit JL, Hicks CW, Engineer RS, Hart KW, Lindsell CJ, Peacock WF,. ST2 in emergency department patients with noncardiac dyspnea. Acad. Emerg. Med. 2013; 20: 1207-1210.
28. Vivodtzev I, Tamisier R, Baguet JP, Borel JC, Levy P, Pepin JL,. Arterial stiffness in COPD. Chest 2014; 145: 861-875.
29. Patel AR, Kowlessar BS, Donaldson GC, Mackay AJ, Singh R, George SN, Garcha DS, Wedzicha JA, Hurst JR,. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013; 188: 1091-1099.
30. Iwamoto H, Yokoyama A, Kitahara Y, Ishikawa N, Haruta Y, Yamane K, Hattori N, Hara H, Kohno N,. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am. J. Respir. Crit. Care Med. 2009; 179: 35-40.
31. Sin DD, Man SF,. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.
32. Williams MC, Murchison JT, Edwards LD, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax 2014; 69: 718-723.
33. Macnee W, Maclay J, McAllister D,. Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2008; 5: 824-833.
34. Wu AH, Wians F, Jaffe A,. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am. Heart J. 2013; 165: 995-999.
35. Willems S, Sels JW, Flier S, Versteeg D, Buhre WF, de Kleijn DP, Hoefer IE, Pasterkamp G,. Temporal changes of soluble ST2 after cardiovascular interventions. Eur. J. Clin. Invest. 2013; 43: 113-120.